Localized Provoked Vulvodynia Clinical Trial
— VVS-01Official title:
Randomized Placebo Controlled Double Blind Study: Efficacy and Safety of Infiltration of the Vestibulum Vaginae With Botulin Toxin in Patients With Localized Provoked Vulvodynia.
| Verified date | June 2018 |
| Source | University Hospital, Ghent |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
In this study we will investigate the efficacy and safety of infiltration of the vestibulum
vaginae with botulin toxin in women who were diagnosed with localized provoked vulvodynia. In
literature covering this subject we find that the prevalence of this condition is between 10
and 15%. Especially young, sexually active women suffer from this problem and some of them
are not capable of having sexual relations with their partner because of this burning pain.
The most probable explanation for the physiopathological mechanism is an increase of nerve
endings in the epithelium of the vestibulum, with an increase and activation of pain
receptors in the vestibular mucosa. It also seems that patients with vestibulodynia have a
higher tonus of the pelvic floor muscles, a greater muscle contraction in response to pain
and a lower capacity of relaxation.
Botulin toxin (Botox) is a neurotoxin that causes a temporary paralysis of the muscle cells.
That way it can decrease the increased tension of the pelvic floor muscles Botox also
inhibits the pain receptors in the vestibulum.
Patients will be recruited through the gynecology consultations. Every patient with localized
provoked vulvodynia that has tried previous treatments (pelvic floor muscle therapy,
antidepressants, anti-epileptics, local anesthetics) will undergo Q-tip testing. If positive
and there are no underlying diseases, the patient will be invited to participate in the study
and after oral and written informed consent, will be included in the study population. Every
6 weeks there will be given injections with 50 units of botulin toxin, on 6 different spots
in the vestibulum. 50 % of the subjects will receive physiological water instead of Botox
(control population). After 3 sessions, we will assess if there is any difference in provoked
pain in treated patients vs. placebos through Q-tip testing.
| Status | Completed |
| Enrollment | 5 |
| Est. completion date | June 19, 2018 |
| Est. primary completion date | November 13, 2014 |
| Accepts healthy volunteers | No |
| Gender | Female |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - +18 years, of sound mind - Dutch speaking - Previously treated for this condition with neuropathic pain medication (antidepressants and anti-epileptics) - in good health Exclusion Criteria: - systemic diseases - pregnancy |
| Country | Name | City | State |
|---|---|---|---|
| Belgium | University Hospital Ghent | Ghent |
| Lead Sponsor | Collaborator |
|---|---|
| University Hospital, Ghent |
Belgium,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | to evaluate the efficacy and safety of botulin toxin in alleviating dyspareunia associated with localized provoked vulvodynia. | Before each session (every 6 weeks) and after the last session the patients will have to fill in a FSFI questionnaire. This way we can evaluate the influence of the therapy on the patients' sexual wellbeing. (efficacy) Before each sessions and 6 weeks after the last injection, patients will undergo Q-tip testing. This way we can objectively evaluate the pain score over the vestibulum. (efficacy) Recording of self-reported side-effects |
every 6 weeks up to week 18 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02892214 -
The Reciprocal Relations Between Psychosocial Characteristics and the Progression of Vestibulodynia
|